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Aims: This study aimed to determine the association of plasma neuroﬁlament light (NfL), a
marker of neurodegeneration, with diabetes status and glycaemic parameters in people
with normal glycaemia (NG), pre-diabetes (PD) and type 2 diabetes (T2D).
Methods: Clinical and descriptive data for the diagnostic groups, NG (n=30), PD (n=48)
and T2D (n=29), aged between 40 and 75 years were included in this cross-sectional
analysis. Plasma NfL levels were analyzed using the ultra-sensitive single-molecule array
(Simoa) platform.
Results: A positive correlation was evident between plasma NfL and fasting glucose (r =
0.2824; p = 0.0032). Plasma NfL levels were not correlated with fasting insulin and
insulin resistance. Plasma Nﬂ levels were signiﬁcantly different across the diabetes
groups (T2D >PD >NG, p=0.0046). Post-hoc analysis indicated signiﬁcantly higher
plasma NfL levels in the T2D [12.4 (5.21) pg/mL] group than in the PD [10.2 (4.13) pg/
mL] and NG [8.37 (5.65) pg/mL] groups. The relationship between diabetes status and
NfL remained signiﬁcant after adjusting for age, sex, BMI, HOMA-IR and physical activity
(adjusted r2 = 0.271, p = 0.035).
Conclusions: These results show biomarker evidence of neurodegeneration in adults at
risk or with T2D. Larger sample size and longitudinal analysis are required to better
understand the application of NfL in people with risk and overt T2D.
Keywords: biomarkers, cross-sectional study, insulin resistance, neurodegeneration, neuroﬁlament light chain,
type 2 diabetes
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peripheral neuropathy (24). Therefore, plasma levels of NfL may
be an attractive indicator of neurodegeneration in people with
different glycaemic status. The current study aimed to investigate
the association of plasma NfL levels with glycaemic control and
diabetes status in a cross-sectional study designed to provide
initial evidence of plasma NfL levels as a possible marker for
early detection of diabetic neuropathy.

INTRODUCTION
Diabetes mellitus (DM) is associated with complications
involving the retina, kidneys, and peripheral nerve (1).
Exceptional control of diabetes-related hyperglycaemia may
slow the progression or prevent the development of diabetic
complications altogether, however, the reversal of complications
does not occur. Among these complications, DM selectively
targets the peripheral nervous system in a widespread or
diffused fashion leading to polyneuropathy or selectively
causing focal neuropathies (diabetic neuropathy) (2). Existing
evidence suggests that this neuropathy can develop in both prediabetes and an overt DM state (3). The prevailing view of the
underlying pathophysiology is axonal degeneration and
progressive loss of nerve ﬁbres (4). Procedures including
needle examination and skin punch biopsies are often required
for the diagnosis of neuropathy when small ﬁber injury is the sole
pathology (5) and can often be painful and inconvenient to the
patient. It is essential for research and clinical practice to have a
feasible test that can reliably detect and monitor such damage.
Neuro-axonal damage is a consequence of many neurological
diseases such as multiple sclerosis, stroke, dementias, including
Alzheimer’s disease (AD) and contributes to cognitive deﬁcits
and physical disability (5). Evidence from epidemiological,
clinical and animal studies has established strong links between
type 2 diabetes (T2D) and neurodegeneration (6–8). The key
mechanisms that underpin these are evolving rapidly (9). Still,
current evidence links to the involvement of insulin signalling
dysfunction (10, 11), inﬂammatory and oxidative stress (12),
pathways that occur early in the neurodegenerative process (13).
Recently, neuroﬁlament (Nf) protein, a neurodegeneration
marker, has gained increasing attention in this space. Nf is a
crucial axonal cytoskeletal component comprising neuroﬁlament
light chain (NfL), neuroﬁlament medium chain (NfM), and
neuroﬁlament heavy chain (NfH) (14). The disruption of Nf in
neuronal damage occurring within neurodegenerative conditions
results in the release of Nf into the cerebrospinal ﬂuid (CSF),
consequently giving rise to elevated NfL concentrations in the
CSF and blood, as seen in neurodegenerative diseases (15–17).
Until recently, studies were limited to CSF NfL, because
detection systems were not sensitive enough to quantitate the
physiologically lower levels of NfL in the blood (18). This has
changed with the introduction of the single-molecule array
(Simoa) technology (19), which now provides the analytical
basis for highly sensitive quantitation of the NfL subunit in the
blood (20). Several studies have demonstrated high correlation
between CSF and plasma NfL levels, and this has given reason to
study NfL in a wide range of neurological disorders (21). Higher
plasma NfL levels have been associated with compromised
cognition and hippocampal atrophy in both cross-sectional
and longitudinal human studies (22). Plasma NfL levels were
also inversely associated with brain glucose metabolism,
longitudinally in the highly characterized Alzheimer’s Disease
Neuroimaging Initiative (ADNI cohort) (23). A previous report
indicated a positive correlation between NfL mRNA levels and
Douleur Neuropathique 4 questionnaire score in pre-diabetic
patients, indicating an early detection marker of pre-diabetic
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METHODOLOGY
Participants
Participants with normal glycaemic control (NG), pre-diabetes
(PD), and T2D were recruited from the Newcastle and Hunter
region (New South Wales, Australia) by radio announcements,
newspaper articles and advertisements placed around the local
community. Our investigation was based on data and baseline
blood samples obtained from the ‘curcumin and omega-3 fatty
acids for the prevention of T2D’ (COP-D trial,
ACTRN12615000559516) for individuals with pre-diabetes,
‘curcumin and omega-3 fatty acids for the management of
dyslipidaemia in T2D’ (CALFOR-CVD trial,
ACTRN12616001483448) for individuals with T2D, and ‘plant
sterols and curcumin for the prevention of cardiovascular
disease’ (PAC-CVD trial, ACTRN12615000956505) for
individuals with normal plasma glucose levels. The detailed
methodology of these studies have been previously published
(25–27). The mean duration of diabetes was 6.0 ± 0.9 years in
people with T2D, and there were no diabetic complications
reported in these patients at the time of recruitment. Seventy
four percent of the total participants in T2D group were taking
oral anti-hyperglycaemic medications along with 67% on antihypertensive medications, 55% on cholesterol lowering
medications and 11% on over-the-counter supplements. From
all recruited subjects, participants aged between 40-75 and those
recruited between 2016-2017 were included in the ﬁnal analysis
for the current study (n=107). The study protocols for all three
clinical trials were approved by the Human Research Ethics
Committee of the University of Newcastle, Callaghan, Australia,
and written informed consent was obtained from all participants.

Blood Samples
Fasting blood samples (10 h) were collected into EDTA
vacutainers via venipuncture by a trained phlebotomist and
plasma fractions were obtained by centrifuging (Heraeus
Biofuge Stratos) for 10 min at 3000 ×g at 4°C. Plasma samples
were aliquoted and stored at −80°C until further analysis. Fasting
plasma glucose was measured on a VP auto analyzer using
Pathology North Services standardized reagents. Insulin was
measured by chemiluminescent microparticle immunoassay
(CMIA), Abbott Architect method, by Pathology North service.

Insulin Resistance and Body
Weight Measurements
Insulin resistance was estimated using the homeostatic model
assessment (HOMA-IR). This is based on the formula fasting
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were established to determine independent determinants of NfL
levels. Unadjusted and adjusted (for age, sex, BMI, HOMA-IR
and physical activity) regression analyses were carried out for
NfL and diabetes status (NG, PD, and T2D). A two-sided p-value
(p)< 0.05 was considered to be statistically signiﬁcant.

glucose (mmol/l) X fasting insulin (µIU/L)/22.5. The height of the
participants was measured using a wall-mounted stadiometer with
a movable headpiece. Weight and BMI were calculated using
bioelectrical impedance (BIA) (InBody230, Biospace Co.).
Measurements were collected in the fasting state whilst standing.
Participants refrained from vigorous physical activity and alcohol
consumption 24 h before data collection. A physical activity
questionnaire (International Physical Activity Questionnaire;
IPAQ Long Form Last 7 Days Self-Administered Format,
October 2002) was used to collect physical activity data.

RESULTS
Clinical and descriptive data for the diagnostic groups, NG
(n=30), PD (n=48) and T2D (n=29) are presented in Table 1.
The plasma glucose levels were signiﬁcantly higher in the PD [5.6
(1) mmol/L] and T2D [7.8(2.5) mmol/L] group than in the NG
group [5(0.6) mmol/L]. Similarly, fasting insulin levels were
signiﬁcantly higher in people with PD [10.1(7.6) mIU/L]
compared to NG. However, there were no differences observed
in the HOMA-IR levels between the PD and NG groups
(Table 1). The T2D group [3.8(3.2)] had signiﬁcantly higher
insulin resistance than the PD and NG group. Participants in the
NG group [52(14) years] were signiﬁcantly younger than those in
T2D group [67(14)], but there was no statistically signiﬁcant
difference between the age of participants in the NG and PD
groups. Compared to NG, BMI was signiﬁcantly higher in PD
and T2D (Table 1). Physical activity levels were signiﬁcantly
lower in the PD and T2D groups than in the NG group (Table 1).

NfL Measurements
All plasma samples were analyzed by ultra-sensitive singlemolecule array (Simoa) assay at Edith Cowan University,
Western Australia, Australia, following manufacturer’s
instructions (28). Calibrators, internal controls and samples
were run in duplicates. Internal controls and samples were
diluted fourfold.

Statistical Analysis
Statistical analysis was performed using Stata/IC 14.2 (StataCorp
LP, Texas, USA). Shapiro-Wilk test was employed to test the
assumption for normality. Normally distributed variables are
reported as mean ± SEM and non-normally distributed variables
as median (Interquartile range, IQR). Pearson correlation for
normally distributed data and Spearman correlation for nonnormally distributed data were employed for correlation
analyses. For comparison across groups, Analysis of variance
(ANOVA) was used for normally distributed data and the
Kruskal Wallis test for non-normally distributed data. For
signiﬁcant effects, Tukey’s HSD or Dunn’s test was used to
perform post hoc comparisons to test the difference in the
dependable variables between NG, PD, and T2D groups. Log
transformation was applied to obtain the normality for NfL levels
and other non-parametric variables. Multiple regression models

Plasma NfL Levels in NG, PD and
T2D Groups
Plasma NfL levels were signiﬁcantly different across the diabetes
groups (T2D > PD > NG, P=0.0046). Post-hoc analysis indicated
signiﬁcantly higher plasma NfL levels in the T2D [12.4 (5.21) pg/
mL] group than the PD [10.2 (4.13) pg/mL] and the NG [8.37
(5.65) pg/mL] groups (Figure 1). Similarly, compared to the NG
group, plasma NfL levels were signiﬁcantly elevated in the PD
group (Figure 1).

TABLE 1 | Participant characteristics.
Parameters
Age (years)
Sex (m/f)
Body mass index (kg/m2)
Waist circumference (cm)
Skeletal muscle mass (kg)
Fat mass
(kg)
Fasting plasma glucose (mmol/L)
Fasting plasma insulin (µIU/L)
HOMA-IR
Total cholesterol
Total : HDL-Cholesterol
Triglycerides
CRP
Physical activity (MET-minutes/week)

Normoglycaemia (n=30)
a

52 (14)
14/16
27.6 ± 0.9b,c
93 ± 2.2d,e
30.5 ± 1.5f
25.4 ± 2.0g

Pre-diabetes (n=48)
59 (15)
20/28
31.4 ± 0.7b
104.2 ± 1.7d
54.7 ± 1.6
33.4 ± 1.7g

5 (0.6)h,i
6.8 (3.8)j,k
1.4 (1.2)l
6.2 ± 0.2n,o
4.7 ± 0.2
1.75 (0.7)p
3.1 (2.3)
3402 (5907)k

5.6 (1)h
10.1 (7.6)j
1.4 (1.2)m
5.7 ± 0.2n
4.4 ± 0.2
1.5 (0.5)
3.8 (2.7)
2944 (4087)l

Type 2 diabetes (n=29)
67 (14)a
19/10
31.5 ± 1.1c
112 ± 2.8e
34.4 ± 1.4f
32.5 ± 2.5
7.8 (2.5)i
10.8 (8.2)k
3.8 (3.2)l,m
4.7 ± 0.2°
4.3 ± 0.2
2.4 (0.8)p
4.1 (3)
1710 (2016)k,l

Data is presented as mean ± SEM or median (Interquartile range). HOMA-IR, homeostatic model assessment for insulin resistance; Physical activity is measured using International
Physical Activity Questionnaire – Long Form, version 2002. Signiﬁcance is set at P < 0.05. Mean or medians with the same small letter represent signiﬁcant (p < 0.05) differences.
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FIGURE 1 | Plasma Neuroﬁlament light (NFL) concentrations in individuals with normal glucose levels, pre-diabetes and type 2 diabetes. In the box-whisker plots
central bar indicate the median NFL concentration and upper and lower boundaries. Blue dots represent the NFL data points. P-values representing differences in
plasma NfL levels between the groups were obtained from Post-hoc analysis (Dunn's test).

Correlation of Plasma NfL Levels and
Study Outcomes

Linear Regression Models for Predictors
of Plasma NfL

A signiﬁcant positive correlation (r = 0.5038; p < 0.0001) was
detected between the participants’ age and their plasma NfL
levels. Plasma NfL correlated (r = 0.2824; p = 0.0032) with
plasma fasting glucose levels (Figure 2). However, no signiﬁcant
(p>0.05) associations were observed for fasting plasma insulin
(r = -0.0356), HOMA-IR (r = 0.0665), BMI (r = -0.0504) and
physical activity (r = 0.1511) with plasma NfL levels.

Unadjusted regression analysis indicated that participants’
diabetes status (i.e., NG, PD, T2D) was a signiﬁcant predictor
of plasma NfL levels (Table 2). However, categorical analysis
showed that only T2D diagnosis (b-coefﬁcient= 0.366, p= 0.001),
over PD and NG, predicted plasma NfL levels. T2D diagnosis
accounts for 36% increase in the outcome variable, plasma NfL
levels. Participants’ age and plasma glucose levels also

FIGURE 2 | Scatter plots for Neuroﬁlament light chain (NfL) and diabetes status. r-value represents the correlation between the blood glucose levels and NfL.
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TABLE 2 | Linear regression models for predictors of plasma neuroﬁlament light (NfL) levels.
b-coefﬁcient

Unadjusted models

Outcome variable

Log(NfL)

Predictors
log(Age)
Sex
Log(HOMA-IR)
Log(Insulin)
Log (glucose)
Diabetes status
Pre-diabetes
Type 2 diabetes

95%CI

1.208
-.1417
0.039
-0.029
0.433
0.180
0.173
0.366

Lower

Upper

0.807
-2.996
-0.078
-0.190
0.148
0.081
-0.009
0.161

1.609
0.016
0.157
0.132
0.719
0.285
0.356
0.571

Adjusted R2

Model-p-value

0.2538
0.0200
0.0005
0.0013
0.0710
0.1082

< 0.001
0.078
0.506
0.722
0.003
0.005
0.063
0.001

0.2408

< 0.001

Adjusted model 1
Log(NfL)

Diabetes_status
Pre-diabetes
Type 2 diabetes
Log(age)
Sex (females)
Log(BMI)
Log(HOMA-IR)
Physical activity

0.070
0.271
1.050
-0.015
-0.226
-0.072
-0.007

-0.133
0.019
0.577
-0.173
-0.758
-0.231
-0.00001

0.274
0.523
1.522
0.141
0.305
0.087
-0.00003

Diabetes status
Prediabetes
Type 2 diabetes
Log(CRP)

0.198
0.377
0.123

0.021
0.180
0.045

0.375
0.573
0.201

0.496
0.035
< 0.001
0.841
0.400
0.371
0.587

Adjusted model 2
0.1641

0.001

0.002

Model 1 adjusted for age, sex, body mass index (BMI), homeostatic model assessment for insulin resistance (HOMA-IR) and physical activity; Model 2 adjusted for C-reactive protein.

signiﬁcantly predicted plasma NfL levels (Table 2). Signiﬁcance
of diabetes status (adjusted r2 = 0.271, p = 0.035) remained after
adjusting for age, sex, BMI, HOMA-IR and physical activity
levels (Table 2). When adjusted for CRP (as a marker of systemic
inﬂammation), both pre-diabetes and diabetes mellitus
accounted for an increase of 19% and 37% in plasma NfL
levels (adjusted model 2, Table 2). Contrastingly, fasting
insulin and HOMA-IR were not signiﬁcant predictors of
plasma NfL levels in this cohort.

fasting plasma insulin or IR status in this cohort. Similarly, BMI and
physical activity levels of the participants did not inﬂuence plasma
NfL levels. In line with previous studies (28, 32), there was no
association or accountability of sex on the plasma NfL levels
between the diabetes diagnostic groups.
T2D has been associated with an increased risk of
neurodegenerative diseases (33–35). Hyperglycaemia in T2D
and PD is linked to neurodegeneration and structural brain
abnormalities (lacunar infarcts, white matter hyperintensities,
brain atrophy etc.) (7, 34, 36). Neurodegeneration is also evident
in diabetic microvascular complications (37, 38). Several
potential mechanisms between hyperglycaemia and
neurodegeneration were previously published (9). These
mechanisms include direct effects through advanced glycation
end products, oxidative stress, IR and inﬂammation (9).
Evidence suggests that peripheral nerve injury occurs during
the early stages of the disease with mild glycaemic dysregulation
(3). A prospective clinical study that included patients with prediabetes, and age- and sex-matched controls, indicated higher
NfL mRNA levels in prediabetics than in controls (24). NfL
mRNA levels were signiﬁcantly higher in PD individuals with
peripheral neuropathy than those without (24), suggesting that
blood NfL mRNA levels could serve as a surrogate marker for
early prediction of pre-diabetic peripheral neuropathy. Results
from the current study substantiate the relationship between
elevated plasma NfL levels with worsening glycaemic status (PD
and T2D). Together, these observations indicate NfL levels could
reﬂect the extent of neurodegeneration in those at risk and with
overt T2D. Another cross-sectional analysis also showed elevated

DISCUSSION
This study reports for the ﬁrst time that plasma NfL levels are
associated with the clinical classiﬁcation of diabetes status and
glycemic control. The novel ﬁndings include (i) elevated levels of
NfL in individuals with T2D and PD, (ii) diabetes diagnostic status
as a signiﬁcant determinant of plasma NfL levels even after
adjusting for confounders such as age, sex, BMI, HOMA-IR,
physical activity and CRP, (iii) plasma NfL levels positively
correlated with fasting plasma glucose, (iv) no correlation between
plasma NfL levels and fasting insulin and IR, suggesting that in
people at risk of T2D and newly diagnosed T2D, glycaemic control
may be the primary modiﬁable risk factor for neurodegeneration.
Plasma NfL levels may be used to determine the risk of
neurodegeneration in individuals with T2D and PD. Consistent
with previously published reports, we found a signiﬁcant positive
association between age and plasma NfL levels (29–31). However,
we did not ﬁnd any association between plasma NfL levels with
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PET and with reduced grey matter volume (r2 = 0.37, p = 0.01)
corrected for age and sex, suggesting IR has a signiﬁcant impact on
neurodegeneration (51). Another study evaluating CSF markers of
AD, indicated no difference in CSF AD markers between
individuals with IR and without IR, including CSF NfL levels
(52). To date, there are no studies reported on the association
between IR and plasma NfL levels. In the current study, we
observed no association between plasma NfL levels and HOMAIR. Further studies are required to validate these ﬁndings and
determine the relationship between HOMA-IR and NfL.
Strengths of the current study include the ﬁrst report on the
association of plasma NfL levels with worsened glycaemic status,
even after adjusting for age and other confounders. Furthermore,
we also reported that plasma NfL levels is only associated with
fasting plasma glucose levels, but not fasting plasma insulin
levels. Including an arm with normal glycaemic control, PD and
T2D, allowed us to study neurodegeneration (as measured by
NfL) in individuals with varying glycaemic controls. This study
also used a highly sensitive immunoassay for measuring plasma
NfL levels. There are several limitations to the current study also
such as the cross-sectional study design, with the inability to
determine direct causality. Secondly, this study is a secondary
analysis and thus lacks the exploration of other markers of
neurodegeneration. Thirdly, the study cohort consists of trial
subjects recruited as part of three different clinical trials carried
out during the same period (2016-2017), and therefore the
current ﬁndings may need validation in a single cohort with
individuals of various glycaemic status. Fourthly, results from
this study are preliminary and need further conﬁrmation in
larger and longitudinal cohorts to determine the utility of NfL in
individuals with risk of T2D and overt T2D. Lastly, our study
cohort also has an uneven number of individuals across the three
groups. Recent ﬁndings indicate that blood NfL level might be
partially affected by renal function (53). Renal function should be
considered while assessing the relationship of NfL with other
metabolic parameters. Therefore, future studies are warranted to
examine the association between NfL and the risk or severity of
neurodegeneration in T2D and its associated complications.

levels of plasma NfL in patients with inherited peripheral
neuropathy compared to healthy controls (39). Plasma NfL
levels were also linked to the severity of the disease (39).
Although NfL may not be speciﬁc, it may be used to predict
the severity of neurodegeneration across the spectrum of T2D
disease progression.
Axonal damage is often evident in sub-clinical cerebrovascular
diseases such as stroke (40), and this is identiﬁed by white matter
lesions on magnetic resonance imaging (40). These observations
have been shown to be predictive of clinical stroke (41). However,
a blood test could be more economical and easier to detect these
changes. A recent study found that serum NfL levels strongly
predict incident stroke in study participants with diabetes who
were stroke-free at baseline in a dose-dependent manner (42).
The predictive capacity of NfL was substantially greater than
established risk factors, with the highest quintile of NfL having an
11.4-fold higher hazard of stroke than the lowest quintile
(unadjusted stroke hazards of other quartiles were 4.16, 4.91,
and 6.49) (42). After adjusting for the Framingham stroke risk
score and ethnicity, the highest quintile had a hazard ratio nearly
10 times greater than those in the lowest quintile (42). This study
also reported that the addition of plasma NfL levels to the
Framingham model signiﬁcantly improved the discriminatory
power of the Framingham risk score for stroke. Thus, indicating
the importance of measuring serum NfL in T2D and those at risk
of T2D for the prediction and possible early detection of diseases
associated with neurodegeneration. In a cross-sectional analysis
from the Swiss Atrial Fibrillation (Swiss-AF) cohort study (43),
history of diabetes mellitus accounted for 26.8% increase in the
serum NfL levels, similar to a magnitude of 10 years increase in
age. While the mechanism remains unknown, a potential
mechanism might involve diabetes induced neuronal damage.
Similar to other cross-sectional studies (44, 45), we have also
replicated the observations of a positive association between age
and plasma NfL levels. A strong association between age and NfL
levels have also been demonstrated by a previous longitudinal
study (32). Despite the positive correlation between NfL and age,
glycaemic status remained a signiﬁcant predictor of plasma NfL
levels in the current study. However, individuals diagnosed with
T2D indicated relatively higher plasma NfL levels than those
with PD and normal glucose tolerance. The plasma NfL levels
were reﬂective of the cut-offs presented in the younger
population for neurodegenerative disorders. Diabetes is a
progressive disease, and the risk increases with age, particularly
in middle-aged adults (40-60 years, with an average onset of
diagnosis at 45 years) (46, 47). Given the signiﬁcant association
of diabetes and neurodegeneration, age speciﬁc NfL levels will be
required to determine the severity of neurodegeneration in
people at risk and with T2D.
Insulin plays a crucial role in brain health, and IR can
contribute to neurodegenerative disorders, such as AD and
vascular cognitive impairment (48). Several studies have
investigated the relationship between IR in the periphery and
brain in AD and related disorders (49, 50). Moreover, in a nondiabetic population of AD subjects, HOMA-IR was associated
with reduced cerebral glucose metabolism measured by [18F]FDG
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CONCLUSION
Plasma NfL level is associated with diabetes status and plasma
glucose levels but not plasma insulin levels or HOMA-IR in a
cohort of middle-aged adults with PD and T2D. The addition of
plasma NfL levels to the panel of existing clinical tests might
improve the determination of risk of neurodegeneration in both
people with risk of T2D and overt T2D. While these study
ﬁndings are preliminary, if validated in longitudinal cohorts with
a larger sample size, we believe plasma NfL levels could become a
marker of severity of neurodegeneration in relation to worsening
glycaemic status in diabetes mellitus.
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